Drug Discovery Today 2014 v.19 №03

London, UK.: Elsevier. — 224 p.Since its launch in 1996, Drug Discovery Today has been at the cutting edge of the science underpinning drug discovery and development. Drug Discovery Today delivers highly current reviews to the readers, not only addressing the rapid scientific developments in drug discovery associated technologies, but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.The utility of biomarkers in CNS drug development
Alan M. PalmerTreating osteoporosis by targeting parathyroid hormone to bone
T. Ponnapakkam, R. Katikaneni, J. Sakon, R. Stratford and R.C. GensureThe development speed paradox: can increasing development speed reduce R&D productivity?
Dennis W. Lendrem and B. Clare LendremNatural products as lead structures: chemical transformations to create lead-like libraries
Mauro Pascolutti and Ronald J. QuinnProtein disulfide isomerase: a promising target for cancer therapy
Shili Xu, Saranya Sankar and Nouri NeamatiAdipokines as drug targets in joint and bone disease
Morena Scotece, Javier Conde, Katriina Vuolteenaho, Anna Koskinen, Veronica López, Juan Gómez-Reino, Francisca Lago, Eeva Moilanen and Oreste GualilloTargeting the nucleolus for cancer-specific activation of p53
Denis Drygin, Sean E. O’Brien, Ross D. Hannan, Grant A. McArthur and Daniel D. Von HoffComputational proteomics: designing a comprehensive analytical strategy
Wilson Wen Bin Goh and Limsoon WongIn vitro-in vivoextrapolation of drug-induced proarrhythmia predictions at the population level
Sebastian Polak, Barbara Wis´niowska, Kamil Fijorek, Anna Glinka and Aleksander MendykCan pharmaco-electroencephalography help improve survival of central nervous system drugs in early clinical development?
Frederick J. Wilson, Steven C. Leiser, Magnus Ivarsson, Søren R. Christensen and Jesper F. BastlundDriving external chemistry optimization via operations management principles
F. Christopher Bi, Heather N. Frost, Xiaolan Ling, David A. Perry, Sylvie K. Sakata, Simon Bailey,
Yvette M. Fobian, Leslie Sloan and Anthony WoodControlling 2-arachidonoylglycerol metabolism as an anti-inflammatory strategy
Mireille Alhouayek, Julien Masquelier and Giulio G. MuccioliBearing arms against osteoarthritis and sarcopenia: when cartilage and skeletal muscle find common interest in talking together
Frédéric De Ceuninck, Armel Fradin and Philippe PastoureauIs bisphosphonate therapy compromised by the emergence of adverse bone disorders?
E. Verron and J.M. BoulerThe conformational musings of a medicinal chemist
Harry FinchDrug enterohepatic circulation and disposition: constituents of systems pharmacokinetics
Yu Gao, Jingwei Shao, Zhou Jiang, Jianzhong Chen, Songen Gu, Suhong Yu, Ke Zheng and Lee JiaReducing attrition in drug development: smart loading preclinical safety assessment
Ruth A. Roberts, Stefan L. Kavanagh, Howard R. Mellor, Christopher E. Pollard, Sally Robinson and
Stefan J. PlatzVirtual pharmaceutical companies: collaborating flexibly in pharmaceutical development
Simon P. Forster, Julia Stegmaier, Rene Spycher and Stefan SeegerDiary